Every open market buy and sale of Zymeworks Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $6.4M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when ZYME insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an ZYME officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every ZYME insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 18, 2026 | Scott PlatshonEVP, Chief Business Officer | Sale | 15,292 | $24.95 | $382K | 21,745 | Nov 18Form 4 |
| Nov 13, 2026 | Paul Andrew MooreChief Scientific Officer | Sale | 39,741 | $26.07 | $1M | 33,756 | Nov 16Form 4 |
| Oct 9, 2026 | Adam SchayowitzEVP, Head of R&D | Sale | 13,832 | $25.85 | $358K | 23,205 | Oct 9Form 4 |
| Jan 12, 2026 | Mark HollywoodEVP & COO | Sale | 6,120 | $22.67 | $139K | 132,913 | Jan 13Form 4 |
| Jan 12, 2026 | Kenneth GalbraithChair & CEO | Sale | 30,424 | $22.67 | $690K | 226,842 | Jan 12Form 4 |
| Jan 12, 2026 | Paul Andrew MooreChief Scientific Officer | Sale | 9,560 | $22.67 | $217K | 48,497 | Jan 12Form 4 |
| Jan 12, 2026 | Jeffrey T L SmithEVP & Chief Medical Officer | Sale | 9,310 | $22.67 | $211K | 26,708 | Jan 12Form 4 |
| Jan 5, 2026 | Paul Andrew MooreChief Scientific Officer | Sale | 20,110 | $25.10 | $505K | 40,391 | Jan 5Form 4 |
| Jan 5, 2026 | Kenneth GalbraithChair & CEO | Sale | 54,343 | $25.10 | $1.4M | 193,266 | Jan 5Form 4 |
| Jan 5, 2026 | Jeffrey T L SmithEVP & Chief Medical Officer | Sale | 10,538 | $25.10 | $265K | 18,352 | Jan 5Form 4 |
| Dec 22, 2025 | Kenneth GalbraithChair & CEO | Sale | 47,528 | $27.02 | $1.3M | 133,275 | Dec 22Form 4 |
| May 19, 2025 | EcoR1 Capital, LLCDirector | Buy | 55,421 | $11.47 | $636K | 17,883,908 | May 19Form 4 |
| Apr 17, 2025 | EcoR1 Capital, LLCDirector | Buy | 128,713 | $11.31 | $1.5M | 17,828,487 | Apr 18Form 4 |
| Apr 4, 2025 | Oleg NodelmanDirector | Buy | 317,208 | $11.43 | $3.6M | 17,699,774 | Apr 7Form 4 |
| Apr 2, 2025 | EcoR1 Capital, LLCDirector | Buy | 127,415 | $11.75 | $1.5M | 17,382,566 | Apr 2Form 4 |
ZYME insider trading FAQ
Are ZYME insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of ZYME on the open market in 0 trades, and 6 sold $6.4M in 11 trades.
When did an ZYME insider last buy shares?
EcoR1 Capital, LLC (Director) bought 55,421 shares for $636K on May 19, 2025, reported on May 19, 2025.
When did an ZYME insider last sell shares?
Scott Platshon (EVP, Chief Business Officer) sold 15,292 shares for $382K on Nov 18, 2026.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
